


REIVINDICACIONES

1. Un compuesto de la Fórmula (I):



o una sal de este aceptable desde el punto de vista farmacéutico, en donde:

R^1 se selecciona del grupo que consiste en (C_1-C_8) alquilo, (C_1-C_8) haloalquilo, hidroxil, (C_1-C_8) alcoxi, (C_5-C_{12}) arilo, heteroarilo de 5-12 miembros, (C_3-C_{10}) cicloalquilo, heterociclilo de 3-12 miembros, OR^4 , SR^4 y $N(R^4)_2$, en donde cada R^4 es independientemente A- R^{14} , en donde A está ausente, es (C_1-C_3) alquilo, $-C(O)-$ o $-SO_2-$, y R^{14} es hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo, heteroarilo de 5-12 miembros, (C_3-C_{10}) cicloalquilo o heterociclilo de 3-12 miembros, o dos R^4 se unen para formar un anillo heterocíclico de 4-6 miembros que contienen 1-3 heteroátomos seleccionados de N, O y S;

R^2 es hidrógeno, halógeno, (C_1-C_8) alquilo, hidroxil, (C_1-C_8) alcoxi o $N(R^5)_2$, en donde cada R^5 es independientemente hidrógeno o (C_1-C_8) alquilo, o dos R^5 se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S;

cada R^3 se selecciona independientemente de hidrógeno, hidroxil, NH_2 ; (C_1-C_8) alquilo o heteroalquilo que tiene 1-8 átomos, o cuando D es $C(R^3)_2$, R^3 también se selecciona de flúor, (C_1-C_8) alquilen o heteroalquilen unidos a un átomo en G para formar un anillo fusionado a G, en donde R^3 se sustituye opcionalmente con 1-6 R^8 ;

cada R^9 es independientemente hidrógeno o flúor;

D es $C(R^3)_2$, NR^3 , O, S o $S(O)_{1-2}$;

G es un (C₅-C₁₂)arilo, o un sistema de anillos de heteroarilo de 5-12 miembros, fusionado a un sistema de anillos de (C₃-C₁₀)cicloalquilo o heterociclilo;

cada R⁸ está ausente o se selecciona independientemente del grupo que consiste en (C₁-C₈)alquilo, (C₁-C₈)haloalquilo, hidroxilo, (C₁-C₈)alcoxi, (C₅-C₁₂)arilo, heteroarilo de 5-12 miembros, (C₃-C₁₀)cicloalquilo, heterociclilo de 3-12 miembros, OR⁴, SR⁴, N(R⁴)₂, CN, halógeno y CON(R⁴)₂, en donde dos R⁸ se unen opcionalmente para formar un anillo espiro-cicloalquilo de 4-6 miembros, un anillo fusionado a cicloalquilo o un puente alquilenos que abarca G, y en donde dos R⁸ se unen opcionalmente para formar carbonilo;

en donde cada R⁴ es independientemente A-R¹⁴, en donde A está ausente, es (C₁-C₃)alquilo, -C(O)- o -SO₂-, y R¹⁴ es hidrógeno, (C₁-C₈)alquilo, (C₅-C₁₂)arilo, heteroarilo de 5-12 miembros, (C₃-C₁₀)cicloalquilo o heterociclilo de 3-12 miembros, o dos R⁴ se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S;

Q está ausente o es una porción divalente seleccionada de O, S, NH y (C₁-C₈)alquilenos; V es N o C si Z está presente, en donde, si V forma un enlace doble, V es carbono, o V es N o CH y forma un enlace doble con W si Z está ausente;

W es N o C, en donde, si W forma un enlace doble, W es carbono;


X es N o C si Y está presente, en donde, si X forma un enlace doble, X es carbono, o X es O, NR¹⁶ o C(R¹⁶)₂ si Y está ausente, en donde R¹⁶ es H o metilo;

Y está ausente, es CR¹⁰, N, NR¹⁰, O o S, o Y está ausente, es hidrógeno o (C₁-C₈)alquilo si Z está ausente, en donde cada R¹⁰ se selecciona independientemente de hidrógeno, (C₁-C₈)alquilo, hidroxilo, (C₁-C₈)alcoxi, halógeno, SH, S-(C₁-C₈)alquilo y N(R¹¹)₂ si Y es CR¹⁰, en donde Y forma un enlace doble con un miembro del anillo adyacente cuando Y es CR¹⁰ o N, y en donde cada R¹¹ es independientemente hidrógeno, (C₁-C₈)alquilo, (C₅-C₁₂)arilo o heteroarilo de 5-12 miembros o dos R¹¹ se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S, o Y es C(R¹⁰)₂, y los dos R¹⁰ y el carbono al que están asociados forman un carbonilo o un tiocarbonilo;

Z está ausente, es CR¹², N, NR¹², O o S, o Z está ausente, es hidrógeno o (C₁-C₈)alquilo si Y está ausente, en donde cada R¹² se selecciona independientemente de hidrógeno, (C₁-C₈)alquilo, hidroxilo, (C₁-C₈)alcoxi, fluoro, cloro, bromo, SH, S-(C₁-C₈)alquilo y N(R¹³)₂, en donde Z forma un enlace doble con un miembro del anillo adyacente si es CR¹² o N, en donde cada R¹³ es independientemente hidrógeno, (C₁-C₈)alquilo, (C₅-C₁₂)arilo o heteroarilo de 5-12 miembros, o dos R¹³ se unen para formar un anillo heterocíclico de

4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S, y en donde Z no es NR¹² si X es N, V es C, W es C, e Y es CR¹⁰, o Z es C(R¹²)₂, y los dos R¹² y el carbono al que están asociados forman un carbonilo o un tiocarbonilo; y cada ----- está ausente o es un enlace opcional, en donde no más de dos ----- no adyacentes pueden estar presentes.

2. Un compuesto de la Fórmula (II):



o una sal de este aceptable desde el punto de vista farmacéutico, en donde:

R¹ se selecciona del grupo que consiste en (C₁-C₈)alquilo, (C₁-C₈)haloalquilo, hidroxil, (C₁-C₈)alcoxi, (C₅-C₁₂)arilo, heteroarilo de 5-12 miembros, (C₃-C₁₀)cicloalquilo, heterociclilo de 3-12 miembros, OR⁴, SR⁴ y N(R⁴)₂, en donde cada R⁴ es independientemente A-R¹⁴, en donde A está ausente, es (C₁-C₃)alquilo, -C(O)- o -SO₂-, y R¹⁴ es hidrógeno, (C₁-C₈)alquilo, (C₅-C₁₂)arilo, heteroarilo de 5-12 miembros, (C₃-C₁₀)cicloalquilo o heterociclilo de 3-12 miembros, o dos R⁴ se unen para formar un anillo heterocíclico de 4-6 miembros que contienen 1-3 heteroátomos seleccionados de N, O y S;

R² es hidrógeno, halógeno, (C₁-C₈)alquilo, hidroxil, (C₁-C₈)alcoxi o N(R⁵)₂, en donde cada R⁵ es independientemente hidrógeno o (C₁-C₈)alquilo, o dos R⁵ se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S;

cada R³ se selecciona independientemente de hidrógeno, hidroxil, NH₂; (C₁-C₈)alquilo o heteroalquilo que tiene 1-8 átomos, o cuando D es C(R³)₂, R³ también se selecciona de flúor, (C₁-C₈)alquilen o heteroalquilen unidos a un átomo en G para formar un anillo fusionado a G, en donde R³ se sustituye opcionalmente con 1-6 R⁸;

cada R^9 es independientemente hidrógeno o flúor;

D es $C(R^3)_2$, O o $S(O)_{1-2}$;

G es un (C_5-C_{12}) arilo, sistema de anillos de heteroarilo de 5-12 miembros;

R^{15} es heteroalquilo que tiene 1-8 átomos unidos a un átomo en G y opcionalmente sustituido con 1-6 R^8 , o R^{15} es heteroalquileno unido a un átomo en G, opcionalmente sustituido con 1-6 R^8 , y unido a un átomo adyacente en G.

cada R^8 está ausente o se selecciona independientemente del grupo que consiste en (C_1-C_8) alquilo, (C_1-C_8) haloalquilo, hidroxilo, (C_1-C_8) alcoxi, (C_5-C_{12}) arilo, heteroarilo de 5-12 miembros, (C_3-C_{10}) cicloalquilo, heterociclilo de 3-12 miembros, OR^4 , SR^4 , $N(R^4)_2$, CN, halógeno y $CON(R^4)_2$, en donde dos R^8 se unen opcionalmente para formar un anillo espiro-cicloalquilo de 4-6 miembros, un anillo fusionado a cicloalquilo o un puente alquileno que abarca G, y en donde dos R^8 se unen opcionalmente para formar carbonilo;

en donde cada R^4 es independientemente A- R^{14} , en donde A está ausente, es (C_1-C_3) alquilo, $-C(O)-$ o $-SO_2-$, y R^{14} es hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo, heteroarilo de 5-12 miembros, (C_3-C_{10}) cicloalquilo o heterociclilo de 3-12 miembros, o dos R^4 se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S;

Q está ausente o es una porción divalente seleccionada de O, S, NH y (C_1-C_8) alquileno;

V es N o C, en donde, si V forma un enlace doble, V es carbono;

W es N o C, en donde, si W forma un enlace doble, W es carbono;

X es N o C, en donde, si X forma un enlace doble, X es carbono;


Y es CR^{10} , N, NR^{10} , O o S, en donde cada R^{10} se selecciona independientemente de hidrógeno, (C_1-C_8) alquilo, hidroxilo, (C_1-C_8) alcoxi, o R^{10} se selecciona opcionalmente de halógeno, SH, S- (C_1-C_8) alquilo y $N(R^{11})_2$ si Y es CR^{10} , en donde Y forma un *[omisión de texto fuente]*doble con un miembro del anillo adyacente cuando Y es CR^{10} o N, y en donde cada R^{11} es independientemente hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo o heteroarilo de 5-12 miembros o dos R^{11} se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S, o Y es $C(R^{10})_2$, y los dos R^{10} y el carbono al que están asociados forman un carbonilo o un tiocarbonilo;

Z es CR^{12} , N, NR^{12} , O o S, en donde cada R^{12} se selecciona independientemente de hidrógeno, (C_1-C_8) alquilo, hidroxilo, (C_1-C_8) alcoxi, o R^{12} se selecciona independientemente de fluoro, cloro, bromo, yodo, SH, S- (C_1-C_8) alquilo y $N(R^{13})_2$ si Z es CR^{12} , en donde Z forma un enlace doble con un miembro del anillo adyacente si es CR^{12} o N, en donde cada R^{13} es independientemente hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo

o heteroarilo de 5-12 miembros, o dos R^{13} se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S, y en donde Z no es NR^{12} si X es N, V es C, W es C, e Y es CR^{10} , o Z es $C(R^{12})_2$, y los dos R^{12} y el carbono al que están asociados forman un carbonilo o un tiocarbonilo; y cada ----- es un enlace opcional, en donde no más de dos ----- no adyacentes pueden estar presentes,

siempre que D sea S(O)1-2 cuando G sea C_{10} arilo o un heteroarilo de 10 miembros.

3. Un compuesto de la Fórmula (III):



o una sal de este aceptable desde el punto de vista farmacéutico, en donde:

cada R^1 se selecciona independientemente del grupo que consiste en (C_1-C_8) alquilo, (C_1-C_8) haloalquilo, hidroxilo, (C_1-C_8) alcoxi, (C_5-C_{12}) arilo, heteroarilo de 5-12 miembros, (C_3-C_{10}) cicloalquilo, heterociclilo de 3-12 miembros, OR^4 , SR^4 y $N(R^4)_2$, en donde cada R^4 es independientemente A- R^{14} , en donde A está ausente, es (C_1-C_3) alquilo, $-C(O)-$ o $-SO_2-$, y R^{14} es hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo, heteroarilo de 5-12 miembros, (C_3-C_{10}) cicloalquilo o heterociclilo de 3-12 miembros, o dos R^4 se unen para formar un anillo heterocíclico de 4-6 miembros que contienen 1-3 heteroátomos seleccionados de N, O y S;

R^2 es hidrógeno, halógeno, (C_1-C_8) alquilo, hidroxilo, (C_1-C_8) alcoxi o $N(R^5)_2$, en donde cada R^5 es independientemente hidrógeno o (C_1-C_8) alquilo, o dos R^5 se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S;

cada R^3 es independientemente hidrógeno, hidroxilo o NH_2 ; o cuando D es $C(R^3)_2$, R^3 también se selecciona de flúor;

cada R^9 es independientemente hidrógeno o flúor;

D es $C(R^3)_2$, O o $S(O)_{1-2}$;

E es NR^1 , CH_2 , $C(R^1)_2$, O o $-S(O)_2$;

cada R^8 está ausente o se selecciona independientemente del grupo que consiste en (C_1-C_8) alquilo, (C_1-C_8) haloalquilo, hidroxilo, (C_1-C_8) alcoxi, (C_5-C_{12}) arilo, heteroarilo de 5-12 miembros, (C_3-C_{10}) cicloalquilo, heterociclilo de 3-12 miembros, OR^4 , SR^4 , $N(R^4)_2$, CN, halógeno y $CON(R^4)_2$, en donde dos R^8 se unen opcionalmente para formar un anillo espiro-cicloalquilo de 4-6 miembros, un anillo fusionado a cicloalquilo o un puente alquilenos que abarca G, y en donde dos R^8 se unen opcionalmente para formar carbonilo;

en donde cada R^4 es independientemente A- R^{14} , en donde A está ausente, es (C_1-C_3) alquilo, $-C(O)-$ o $-SO_2-$, y R^{14} es hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo, heteroarilo de 5-12 miembros, (C_3-C_{10}) cicloalquilo o heterociclilo de 3-12 miembros, o dos R^4 se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S;

Q está ausente o es una porción divalente seleccionada de O, S, NH y (C_1-C_8) alquilenos;

V es N o C, en donde, si V forma un enlace doble, V es carbono;

W es N o C, en donde, si W forma un enlace doble, W es carbono;

X es N o C, en donde, si X forma un enlace doble, X es carbono;


Y es CR^{10} , N, NR^{10} , O o S, en donde cada R^{10} se selecciona independientemente de hidrógeno, (C_1-C_8) alquilo, hidroxilo, (C_1-C_8) alcoxi, halógeno, SH, S- (C_1-C_8) alquilo y $N(R^{11})_2$ si Y es CR^{10} , en donde Y forma un [omisión de texto fuente] doble con un miembro del anillo adyacente cuando Y es CR^{10} o N, y en donde cada R^{11} es independientemente hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo o heteroarilo de 5-12 miembros, o dos R^{11} se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S, o Y es $C(R^{10})_2$, y los dos R^{10} y el carbono al que están asociados forman un carbonilo o un tiocarbonilo;

Z es CR^{12} , N, NR^{12} , O o S, en donde cada R^{12} se selecciona independientemente de hidrógeno, (C_1-C_8) alquilo, hidroxilo, (C_1-C_8) alcoxi, fluoro, cloro, bromo, SH, S- (C_1-C_8) alquilo y $N(R^{13})_2$, en donde Z forma un enlace doble con un miembro del anillo adyacente si es CR^{12} o N, en donde cada R^{13} es independientemente hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo o heteroarilo de 5-12 miembros, o dos R^{13} se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados

de N, O y S, y en donde Z no es NR^{12} si X es N, V es C, W es C, e Y es CR^{10} , o Z es $\text{C}(\text{R}^{12})_2$, y los dos R^{12} y el carbono al que están asociados forman un carbonilo o un tiocarbonilo; y

cada ----- es un enlace opcional, en donde no más de dos ----- no adyacentes pueden estar presentes.

4. Un compuesto de la Fórmula (IV):



o una sal de este aceptable desde el punto de vista farmacéutico, en donde:

cada R^1 se selecciona independientemente del grupo que consiste en $(\text{C}_1\text{-C}_8)$ alquilo, $(\text{C}_1\text{-C}_8)$ haloalquilo, hidroxilo, $(\text{C}_1\text{-C}_8)$ alcoxi, $(\text{C}_5\text{-C}_{12})$ arilo, heteroarilo de 5-12 miembros, $(\text{C}_3\text{-C}_{10})$ cicloalquilo, heterociclilo de 3-12 miembros, OR^4 , SR^4 y $\text{N}(\text{R}^4)_2$, en donde cada R^4 es independientemente A-R^{14} , en donde A está ausente, es $(\text{C}_1\text{-C}_3)$ alquilo, $-\text{C}(\text{O})-$ o $-\text{SO}_2-$, y R^{14} es hidrógeno, $(\text{C}_1\text{-C}_8)$ alquilo, $(\text{C}_5\text{-C}_{12})$ arilo, heteroarilo de 5-12 miembros, $(\text{C}_3\text{-C}_{10})$ cicloalquilo o heterociclilo de 3-12 miembros, o dos R^4 se unen para formar un anillo heterocíclico de 4-6 miembros que contienen 1-3 heteroátomos seleccionados de N, O y S;

R^2 es hidrógeno, halógeno, $(\text{C}_1\text{-C}_8)$ alquilo, hidroxilo, $(\text{C}_1\text{-C}_8)$ alcoxi o $\text{N}(\text{R}^5)_2$, en donde cada R^5 es independientemente hidrógeno o $(\text{C}_1\text{-C}_8)$ alquilo, o dos R^5 se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S;

cada R^3 es independientemente hidrógeno, hidroxilo o NH_2 ; o cuando D es $\text{C}(\text{R}^3)_2$, R^3

también se selecciona de flúor;

cada R^9 es independientemente hidrógeno o flúor;

B es N o C;

E es NR^1 , CH_2 , $C(R^1)_2$, O o $-S(O)_2$;

cada R^8 está ausente o se selecciona independientemente del grupo que consiste en (C_1-C_8) alquilo, (C_1-C_8) haloalquilo, hidroxilo, (C_1-C_8) alcoxi, (C_5-C_{12}) arilo, heteroarilo de 5-12 miembros, (C_3-C_{10}) cicloalquilo, heterociclilo de 3-12 miembros, OR^4 , SR^4 , $N(R^4)_2$, CN, halógeno y $CON(R^4)_2$, en donde dos R^8 se unen opcionalmente para formar un anillo espiro-cicloalquilo de 4-6 miembros, un anillo fusionado a cicloalquilo o un puente alquilenos que abarca G, y en donde dos R^8 se unen opcionalmente para formar carbonilo;

en donde cada R^4 es independientemente $A-R^{14}$, en donde A está ausente, es (C_1-C_3) alquilo, $-C(O)-$ o $-SO_2-$, y R^{14} es hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo, heteroarilo de 5-12 miembros, (C_3-C_{10}) cicloalquilo o heterociclilo de 3-12 miembros, o dos R^4 se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S;

Q está ausente o es una porción divalente seleccionada de O, S, NH y (C_1-C_8) alquilenos;

V es N o C, en donde, si V forma un enlace doble, V es carbono;

W es N o C, en donde, si W forma un enlace doble, W es carbono;

X es N o C, en donde, si X forma un enlace doble, X es carbono;


Y es CR^{10} , N, NR^{10} , O o S, en donde cada R^{10} se selecciona independientemente de hidrógeno, (C_1-C_8) alquilo, hidroxilo, (C_1-C_8) alcoxi, halógeno, SH, $S-(C_1-C_8)$ alquilo y $N(R^{11})_2$ si Y es CR^{10} , en donde Y forma un *[omisión de texto fuente]* doble con un miembro del anillo adyacente cuando Y es CR^{10} o N, y en donde cada R^{11} es independientemente hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo o heteroarilo de 5-12 miembros, o dos R^{11} se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S, o Y es $C(R^{10})_2$, y los dos R^{10} y el carbono al que están asociados forman un carbonilo o un tiocarbonilo;

Z es CR^{12} , N, NR^{12} , O o S, en donde cada R^{12} se selecciona independientemente de hidrógeno, (C_1-C_8) alquilo, hidroxilo, (C_1-C_8) alcoxi, fluoro, cloro, bromo, SH, $S-(C_1-C_8)$ alquilo y $N(R^{13})_2$, en donde Z forma un enlace doble con un miembro del anillo adyacente si es CR^{12} o N, en donde cada R^{13} es independientemente hidrógeno, (C_1-C_8) alquilo, (C_5-C_{12}) arilo o heteroarilo de 5-12 miembros, o dos R^{13} se unen para formar un anillo heterocíclico de 4-6 miembros que contiene 1-3 heteroátomos seleccionados de N, O y S, y en donde Z no es NR^{12} si X es N, V es C, W es C, e Y es CR^{10} , o Z es














$C(R^{12})_2$, y los dos R^{12} y el carbono al que están asociados forman un carbonilo o un tiocarbonilo; y


cada ----- es un enlace opcional, en donde no más de dos ----- no adyacentes pueden estar presentes.

5. El compuesto o la sal aceptable desde el punto de vista farmacéutico de acuerdo con cualquiera de las reivindicaciones 1-4, en donde




se selecciona de:







6. El compuesto o la sal aceptable desde el punto de vista farmacéutico de acuerdo con la reivindicación 5, en donde




se selecciona de:






















































7. El compuesto o la sal aceptable desde el punto de vista farmacéutico de acuerdo con la reivindicación 3, en donde:




se selecciona de:












8. El compuesto o la sal aceptable desde el punto de vista farmacéutico de acuerdo con la reivindicación 7, en donde:




































es:



































9. Un compuesto seleccionado de:



































































1




2




3




4




5




6




7




8




9


















10






























11






















12
































o una sal de este aceptable desde el punto de vista farmacéutico.


10. Un compuesto seleccionado de:






























































o una sal de este aceptable desde el punto de vista farmacéutico.












11. Un compuesto seleccionado de:













































,




,




,




,




,




,




,




,




,















,

































,




,












,




,




,




,




,




,




,




,




,




,














,




























,



,







o una sal de aquel aceptable desde el punto de vista farmacéutico.

12. Un compuesto de acuerdo con cualquiera de las reivindicaciones 1-10, en donde la sal se selecciona de sales de acetato, aspartato, benzoato, besilato, bicarbonato/carbonato, bisulfato/sulfato, borato, camsilato, citrato, edisilato, esilato, formiato, fumarato, gluceptato, gluconato, glucuronato, hexafluorofosfato, hibenzato, clorhidrato/cloruro, bromhidrato/bromuro, yodhidrato/yoduro, isetionato, lactato, malato, maleato, malonato, mesilato, metilsulfato, naftilato, 2-napsilato, nicotinato, nitrato, orotato, oxalato, palmitato, pamoato, fosfato/fosfato de hidrógeno/fosfato de dihidrógeno, sacarato, estearato, succinato, tartrato, tosilato, trifluoroacetato, aluminio, arginina, benzatina, calcio, colina, dietilamina, diolamina, glicina, lisina, magnesio, meglumina, olamina, potasio, sodio, trometamina y zinc.

13. Un compuesto de acuerdo con cualquiera de las reivindicaciones 1-11, en donde la sal se selecciona de sales de clorhidrato, tosilato y mesolato.

14. Una composición farmacéutica que comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1-13, o una sal de este aceptable desde el punto de vista farmacéutico, y un portador aceptable desde el punto de vista farmacéutico.

15. Un método para tratar el crecimiento celular anormal en un mamífero, en donde el método comprende administrar al mamífero una cantidad terapéuticamente eficaz de un compuesto de acuerdo con cualquiera de las reivindicaciones 1-13 o una sal de este aceptable desde el punto de vista farmacéutico.

16. El método de acuerdo con la reivindicación 15, en donde el crecimiento celular anormal es cáncer.

17. El método de acuerdo con la reivindicación 16, en donde el cáncer es cáncer de pulmón, cáncer óseo, cáncer de páncreas, cáncer de piel, cáncer de cabeza o de cuello, melanoma cutáneo o intraocular, cáncer de útero, cáncer de ovarios, cáncer rectal, cáncer de la región anal, cáncer de estómago, cáncer de colon, cáncer de mama, cáncer de útero, carcinoma de las trompas de Falopio, carcinoma del endometrio, carcinoma del cuello uterino, carcinoma de la vagina, carcinoma de la vulva, enfermedad de Hodgkin, cáncer de esófago, cáncer del intestino delgado, cáncer del sistema endócrino, cáncer de la glándula tiroidea, cáncer de la glándula paratiroidea, cáncer de la glándula suprarrenal, sarcoma del tejido blando, cáncer de uretra, cáncer de pene, cáncer de próstata, leucemia crónica o aguda, linfomas linfocíticos, cáncer de vejiga, cáncer de riñón o de uretra, carcinoma de células renales, carcinoma de la pelvis renal, neoplasia del sistema nervioso central (SNC), linfoma primario del SNC, tumores del eje espinal, glioma del tronco encefálico o adenoma pituitario.

18. Uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1-13, o una sal de este aceptable desde el punto de vista farmacéutico, para la preparación de un medicamento útil en el tratamiento del crecimiento celular anormal en un mamífero.
19. El uso de acuerdo con la reivindicación 18, en donde el crecimiento celular anormal es cáncer.
20. El uso de acuerdo con la reivindicación 19, en donde el cáncer es cáncer de pulmón, cáncer óseo, cáncer de páncreas, cáncer de piel, cáncer de cabeza o de cuello, melanoma cutáneo o intraocular, cáncer de útero, cáncer de ovarios, cáncer rectal, cáncer de la región anal, cáncer de estómago, cáncer de colon, cáncer de mama, cáncer de útero, carcinoma de las trompas de Falopio, carcinoma del endometrio, carcinoma del cuello uterino, carcinoma de la vagina, carcinoma de la vulva, enfermedad de Hodgkin, cáncer de esófago, cáncer del intestino delgado, cáncer del sistema endócrino, cáncer de la glándula tiroidea, cáncer de la glándula paratiroidea, cáncer de la glándula suprarrenal, sarcoma del tejido blando, cáncer de uretra, cáncer de pene, cáncer de próstata, leucemia crónica o aguda, linfomas linfocíticos, cáncer de vejiga, cáncer de riñón o de uretra, carcinoma de células renales, carcinoma de la pelvis renal, neoplasia del sistema nervioso central (SNC), linfoma primario del SNC, tumores del eje espinal, glioma del tronco encefálico o adenoma pituitario.